Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

This study aims to explore whether adding immunotherapy bridging treatment for low-risk refractory/relapsed B-NHL can demonstrate better outcomes, in order to find the most effective treatment plan for low-risk patients.

Trial Details

NCT ID
NCT06695013
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • zanubrutinib
  • CAR-T
  • Bridging radiotherapy
  • Tislelizumab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18 or older, regardless of gender.
  • Histologically confirmed B-cell non-Hodgkin lymphoma, according to Lugano diagnostic criteria.
  • At least first-line treatment for relapsed or refractory patients, including chemotherapy regimens containing anthracyclines and anti-CD20 monoclon…
  • No prior CD19 CAR T cell therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →